SCHEMBL1361184

SCHEMBL1361184

Cc1nccn1-c1nc(-c2ccc(Cl)cc2)c(CCCOc2ccccc2CCCO)o1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 3/20 0.35
SIRT2 Q8IXJ6 1/20 0.34
TDP1 Q9NUW8 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GCGR P47871 1/20 0.33
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
KCNH2 Q12809 1/20 0.32
FFAR4 Q5NUL3 1/20 0.31
TP53 P04637 1/20 0.31
DHFR P00374 1/20 0.31
SCNN1A P37088 1/20 0.31
MAPT P10636 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1362894 0.89 RXRA (0.41) PPARDFFAR4DHFR
SCHEMBL963990 0.88 SIRT2 (0.40) SIRT2CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL1362046 0.88 PPARD (0.36) PPARDMEN1USP2CYP1A2CYP3A4
SCHEMBL1361779 0.88 GCGR (0.34) PPARDTDP1L3MBTL1GCGRTP53
SCHEMBL203742 0.87 TP53 (0.41) TDP1L3MBTL1GCGRMEN1TSHR
SCHEMBL962882 0.87 MAPT (0.36) TDP1L3MBTL1GCGRMEN1USP2
SCHEMBL1361746 0.87 GCGR (0.38) TDP1L3MBTL1GCGRMEN1CYP1A2
Hydrochloric Acid SCHEMBL1362475 0.87 TP53 (0.41) TDP1L3MBTL1GCGRMEN1TSHR
SCHEMBL1361418 0.87 MAPT (0.42) TDP1L3MBTL1GCGRMEN1CYP1A2
SCHEMBL965656 0.85 SIRT2 (0.37) SIRT2GCGRCYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067453-B2 Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-29 US disclosed
US-20080269219-A1 Neurotrophin production/secretion promoting agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-7396848-B1 oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-08 US disclosed
EP-1206472-B1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-10-01 EP disclosed
US-6605629-B1 Oxazole derivatives; low toxicity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-12 US disclosed
EP-1206472-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT Takeda Chemical Industries, Ltd. (JP) 2002-05-22 EP disclosed
WO-2001014372-A2 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269219-A1 Neurotrophin production/secretion promoting agent BDNF, NGF, NTRK2 PPARD 2505/4885SIRT2 1453/4885TDP1 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.